N Engl J Med 2018 Oct 20
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Related Questions
Have the results from IMpassion130 changed the standard of care?
New comment by Medical Oncologist at UT Southwestern Medical Center ( December 17, 2018)
The recent update of IMpassion130 by Leisha Emens at San Antonio indicates that PDL1 positivity on immune cells was the best biomarker to predict response to nab-paclitaxel wi...
Received neoadjuvant ddAC/T followed by adjuvant capecitabine for residual disease and found to have metastatic pulmonary nodules within months of sur...
New answer by Medical Oncologist at OHSU, Knight Cancer Institute (May 11, 2023)
I tend to consider immunotherapy first if PD-L1 CPS>=10, unless toxicity is a major issue in a particular patient. In that case, PARPi would be my first choice.
PDL1 status pending; BRCA wild type
New answer by Medical Oncologist at Icahn School of Medicine at Mount Sinai (November 19, 2019)
I would approach this patient with weekly nab-paclitaxel and atezolizumab if she was PDL-1 positive (just like the Impassion Trial, NEJM 2018:379;2018-21). If the tumor (actua...
PD-L1 is low and she has residual neuropathy from neoadjuvant paclitaxel.
New comment by Medical Oncologist at Ohio State University ( July 12, 2020)
I agree that radiation therapy should be the next viable option only for patients with symptomatic skin metastases. I would not consider it for asymptomatic or minimally sympt...
New answer by Medical Oncologist at Ohio State University (November 16, 2020)
The short answer is that 22C3 is not equivalent to SP142. There are cases that are double-positive but 22C3 positive and SP142 negative cases exist. While benefit from atezoli...
In patients with prior perioperative immunotherapy with early relapse, would re-introduction of immunotherapy be reasonable with high TMB?
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (June 22, 2022)
Atezolizumab was granted accelerated approval by FDA in March 2019 based on data from the phase 3 IMpassion130 trial which demonstrated a statistically significant benefit to ...